Enter your e-mail address below
to reset your password.
Please activate your registration
by clicking the link in the activation email
or click submit to resend the activation email.
Please check your spam folder too...
Check your mailbox to activate your registration.
Please check your spam folder too.
Paris-based pharmaceutical company Sanofi will eliminate first-phase R&D activity at its Hungarian subsidiary Chinoin, the latter company’s Communications Director Iván Rózsa told MTI on Tuesday evening.
The move is part of global restructuring of R&D activities within the Sanofi group, he said.
Rózsa emphasized that Chinoin would continue to conduct later-phase R&D activity in the country. These could bear results more rapidly and are export-oriented, he said.
The elimination of initial-phase R&D activity will affect 160 employees at Chinoin, Rózsa said.